Day 1 Program

Educational Session 1: After CDK4/6 Inhibitors—Advancing Treatment for HR+HER2-negative Metastatic Breast Cancer

Day 1: December 9, 2025

2:30 PM–4:15 PM CST

Stars at Night 1-2

Session Details

This educational session focuses on advancing treatment strategies for HR+/HER2-negative metastatic breast cancer after progression on CDK4/6 inhibitors, highlighting next-generation endocrine therapies, emerging resistance-targeting agents, and evolving clinical approaches.

Moderator

Antoinette Tan, Atrium Health, Charlotte, NC

ED1-01

Treatment strategies after CDK4/6 inhibitor progression

Mafalda Oliveira, Vall d'Hebron Institute of Oncology, Barcelona, Spain

ED1-02

Next generation endocrine agents

Erica Mayer, Dana-Farber Cancer Institute, Boston, MA

ED1-03

Emerging agents to overcome CDK4/6 inhibitor resistance

Shom Goel, Peter MacCallum Cancer Centre, Melbourne, Australia

Advocate

Abigail M Johnston, SurvivingBreastCancer.org, Orlando, FL